This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medical Products' Feb 11 Earnings Roster: DXCM, LH & More
by Trina Mukherjee
The Medical Product companies' fourth-quarter results are likely to reflect huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Why LabCorp (LH) Might Surprise This Earnings Season
by Zacks Equity Research
LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings
by Zacks Equity Research
LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results
by Zacks Equity Research
Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.
Why LabCorp (LH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
LabCorp's (LH) Covance Arm Stays Robust Amid Procedure Delay
by Zacks Equity Research
Apart from COVID-19 supports, LabCorp (LH) is making significant strides in other businesses.
Top Ranked Growth Stocks to Buy for January 4th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 4th.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.
Is LabCorp (LH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Top Ranked Growth Stocks to Buy for December 30th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 30th.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Teleflex (TFX) Completes Buyout of Hemostatic Goods Producer
by Zacks Equity Research
Teleflex (TFX) to leverage its strength in enhancing clinical efficacy and patient safety via the recent buyout.
Zacks.com featured highlights include: LabCorp, Honda Motor, Boise Cascade, ODP Corp and General Motors
by Zacks Equity Research
Zacks.com featured highlights include: LabCorp, Honda Motor, Boise Cascade, ODP Corp and General Motors
5 Low Price-to-Book Value Stocks to Buy in the New Year
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
Create a Value-Based Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. ODP Corporation (ODP), Sanmina Corporation (SANM), Laboratory Corporation (LH) and Boise Cascade (BCC) boast low P/CF ratio.
LabCorp (LH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $203.87 in the latest trading session, marking a -0.09% move from the prior day.
Top Ranked Growth Stocks to Buy for December 23rd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 23rd
3 Reasons Growth Investors Will Love LabCorp (LH)
by Zacks Equity Research
LabCorp (LH) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com featured highlights include: AutoNation, Laboratory Corporation, OMI, TTEC and ArcBest
by Zacks Equity Research
Zacks.com featured highlights include: AutoNation, Laboratory Corporation, OMI, TTEC and ArcBest
6 Stocks Near 52-Week Highs That are Poised to Rally Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
LabCorp (LH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $205.11 in the latest trading session, marking a +1.19% move from the prior day.
LH vs. XRAY: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. XRAY: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: ODP Corp, LabCorp, Boise Cascade, Koppers Holdings and Greif
by Zacks Equity Research
Zacks.com featured highlights include: ODP Corp, LabCorp, Boise Cascade, Koppers Holdings and Greif